XOMA Royalty Corporation - Common Stock (XOMA)

As per the amended deal, LAVA shareholders will receive an initial cash payment of $1.04 per share, down from the range of $1.16 to $1.24 initially agreed upon.

October 17, 2025 – In the volatile world of biotechnology, ambitious price targets often fuel investor speculation and market buzz. However, for Turnstone Biologics Corp. (NASDAQ: TSTN), the notion of its stock reaching a $100 valuation stands in stark contrast to its current precarious financial and operational state. Despite the transformative

XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock plus one non-transferable contingent value right.

XOMA stock results show that XOMA missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

FDA's Genetic Metabolic Diseases Advisory Committee will review Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C on August 2. PDUFA decision expected by September 21.

For investors with only a little money to spare, these three supercharged stocks represent an outrageous opportunity for future growth.

XOMA stock results show that XOMA missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

XOMA stock results show that XOMA missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

XOMA acquires Kinnate Biopharma for $2.3352 per share, with potential additional cash. The acquisition is expected to close in April 2024.

  During Monday, 102 stocks hit new 52-week lows.

  During Thursday, 56 stocks hit new 52-week lows.

  On Friday, 57 companies reached new 52-week lows.

Earlier today, XOMA Corporation (NASDAQ: XOMA) acquired the royalty and milestone rights associated with two assets from LadRx Corporation: arimoclomol for Niemann-Pick disease type C, and aldoxorubicin, an albumin-linked formulation of doxorubicin 

  Wednesday saw 59 companies set new 52-week lows.